Vernakalant
Sponsors
Advanz Pharma, Correvio International Sarl, Maastricht University Medical Center, David Filgueiras-Rama, Ottawa Hospital Research Institute
Conditions
Atrial FibrillationParoxysmal Atrial FibrillationPost-cardiac Surgery
Phase 3
A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)
TerminatedNCT00989001
Start: 2009-10-31End: 2010-11-30Updated: 2014-03-10
Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients
Not yet recruitingNCT04748991
Start: 2024-09-30End: 2025-09-30Target: 50Updated: 2024-05-22
Phase 4
A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)
WithdrawnNCT01627106
Start: 2012-09-30End: 2016-03-31Updated: 2013-08-26
Vernakalant Versus Flecainide: Atrial Contractility
NCT01646281
Start: 2012-08-31End: 2013-08-31Target: 70Updated: 2012-07-20
Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents
CompletedNCT03005366
Start: 2017-01-31End: 2023-08-31Updated: 2023-08-07
RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department
CompletedNCT04485195
Start: 2021-06-17End: 2024-11-06Updated: 2025-04-10